Tenon Medical reported Q4 2025 revenue of $1.5M, a 92% increase, and full year revenue of $3.9M, up 20%. Gross margin improved to 69% in Q4 and 60% for FY2025.
Bullish
Tenon Medical achieved FDA clearance for its next-generation system and successful initial procedures, driving significant Q4 2025 revenue and gross margin improvement.
Bearish
Tenon Medical experienced a decline in cash and cash equivalents, continued to report a net loss, and saw increased operating expenses in Q4 2025.